https://charts.traderzeitung.de/phases/US10501L1061 string(1418) "{"isin":"US10501L1061","name":"BrainsWay Ltd","stock_id_xnas":8931191,"stock_id_xnys":137849138,"generated_at":"2026-09-22 22:14:00","days":[{"date":"2026-09-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.61,"close_at":"2026-09-18 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.555,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":-0.4041},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":13.19,"close_at":"2026-09-22 15:28:00","complete":true,"perf_pct":-2.6927},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.61,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":3.1842},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Brainsway Aktie News & Nachrichten

[WKN: A2PCBP | Symbol: BWAY]

Realtimekurs

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.